Anita Y.M. Howe,
Chaturaka Rodrigo,
Evan B. Cunningham,
Mark W. Douglas,
Julia Dietz,
Jason Grebely
m.fl.:
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Kay-Martin Johnsen,
Jon Florholmen,
Øystein Kittel Moe,
Mona Dixon Gundersen,
Julia Beilfuss,
Hege Kileng
m.fl.:
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study
Rasmus Goll,
Øystein Kittel Moe,
Kay-Martin Johnsen,
Renate Weenås Meyer,
Joachim Friestad,
Mona Dixon Gundersen
m.fl.:
Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease
Hege Kileng,
Tore Jarl Gutteberg,
Rasmus Goll,
Eyvind Jakob Paulssen
:
Screening for hepatitis C in a general adult
population in a low-prevalence area: the
Tromsø study
BMC Infectious Diseases 2019
ARKIV /
DOI
Midori Kjellin,
Hege Kileng,
Dario Akaberi,
Navaneethan Palanisamy,
Ann-Sofi Duberg,
Astrid Danielsson
m.fl.:
Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
Scandinavian Journal of Gastroenterology 2019
ARKIV /
DOI
Hege Kileng,
Midori Kjellin,
Dario Akaberi,
Assar Bergfors,
Ann-Sofi Duberg,
Lars Wesslen
m.fl.:
Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy
Scandinavian Journal of Gastroenterology 2018
ARKIV /
DOI
Kay-Martin Johnsen,
Rasmus Goll,
Vegar Hansen,
Trine Olsen,
Renathe Rismo,
Richard Heitmann
m.fl.:
Repeated intensified infliximab induction – results
from an 11-year prospective study of ulcerative colitis
using a novel treatment algorithm
European Journal of Gastroenterology and Hepathology 2017
DOI
Hege Kileng,
Lars Bernfort,
Tore Jarl Gutteberg,
Odd Sverre Moen,
Magnhild Gangsøy Kristiansen,
Eyvind Jakob Paulssen
m.fl.:
Future complications of chronic hepatitis C in a low-risk area: Projections from the hepatitis c study in Northern Norway
BMC Infectious Diseases 2017
ARKIV /
DOI
Jan Sperl,
Gabor Horvath,
Waldemar Halota,
Juan Arenas Ruiz-Tapiador,
Anca Streinu-Cercel,
Ligita Jancoriene
m.fl.:
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial
Journal of Hepatology 2016
DOI
Håvard Midgard,
Benedikte Bjøro,
Arild Mæland,
Konopski Zbigniew,
Hege Kileng,
Jan Kristian Damås
m.fl.:
Hepatitis C reinfection after sustained virological response
Journal of Hepatology 2016
DOI
Kjersti Mevik,
Stig Norderval,
Hege Kileng,
Magnar Johansen,
Barthold Vonen
:
LONG-TERM RESULTS AFTER ANTERIOR SPHINCTEROPLASTY FOR ANAL INCONTINENCE
Scandinavian Journal of Surgery 2009